Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

Publication | Closed Access

DOI

248

Citations

References

2015

Year

Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt, Christo van Niekerk, Peter R. Donald, Divan A. Burger, Robert Schall, Melvin Spigelman, Almari Conradie, Kathleen D. Eisenach,

The Lancet

Pulmonary TuberculosisPhase 2BTuberculosis PreventionPharmacologyTuberculosisPharmacotherapyFirst 8Antimicrobial ChemotherapyMedicineAntimicrobial ResistanceDrug-resistant Pulmonary TuberculosisDrug Resistance